Related Experiment Video

Updated: Dec 13, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.2K

Programmed cell death factor 4 (PDCD4), a novel therapy target for metabolic diseases besides cancer

Kaikai Lu1, Qian Chen1, Mengda Li1

  • 1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, 710061, PR China.

Free Radical Biology & Medicine
|August 4, 2020
PubMed

Insights

Programmed cell death factor 4 (PDCD4) is a tumor suppressor involved in apoptosis and inhibiting cancer progression. Aberrant PDCD4 expression is linked to metabolic diseases, impacting glucose and lipid metabolism.

Area of Science:

  • Molecular Biology
  • Oncology
  • Metabolic Diseases

Background:

  • Programmed cell death factor 4 (PDCD4) is a known tumor suppressor.
  • PDCD4 influences apoptosis, cell proliferation, invasion, and metastasis.
  • Aberrant PDCD4 expression is increasingly linked to metabolic disorders.

Purpose of the Study:

  • To review the structure, expression, and function of PDCD4.
  • To elucidate PDCD4's regulatory mechanisms in cancer and metabolic diseases.
  • To provide insights for diagnosis and treatment of these conditions.

Main Methods:

  • Literature review of recent research on PDCD4.
  • Analysis of PDCD4's role in tumor suppression.
  • Examination of PDCD4's involvement in metabolic disease pathways.

Main Results:

  • PDCD4 regulates glucose and lipid metabolism, insulin resistance, oxidative stress, inflammation, and gut microbiota.
  • PDCD4's dual role in cancer and metabolic disease pathogenesis is highlighted.
  • Understanding PDCD4's mechanisms offers therapeutic potential.

Conclusions:

  • PDCD4 is a critical regulator in both oncogenesis and metabolic homeostasis.
  • Further research into PDCD4 pathways can lead to novel therapeutic strategies.
  • PDCD4 represents a promising target for treating tumors and metabolic diseases.
Keywords:
Glucose metabolismInflammationIntestinal floraLipid metabolismOxidative stressPDCD4

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.0K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.9K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
8.9K